|
Date:9/18/2020 Time:10:00 AM EDT Duration:60 minutes Please join us for an in-depth review of the spinal muscular atrophy (SMA) treatment landscape, which now includes approved drugs from Biogen, Novartis and Roche. Bloomberg Intelligence analysts Marc Engelsgjerd, MD, and Sam Fazeli, PhD, and inThought Research analyst Michelle Rivera, PhD, will be joined by expert speakers Thomas Crawford, MD, and Adrian Krainer, PhD, for a discussion of key attributes of Spinraza, Zolgensma and newcomer Evrysdi and how they might be used going forward. Speakers |
First Name
|
Last Name
|
Company Name
|
Email Address
|
Phone Number
|
Industry
|
Job Role
|
City
|
State/Province
|
For UK registrations, please select British Isles. |
 |
Country
|
Would you like to be contacted by a Bloomberg representative to schedule a demonstration?
|
By submitting this information, I agree to the privacy policy and to learn more about products and services from Bloomberg. |
|
|
|
|